TY - JOUR
T1 - Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients
AU - Chalmers, J. P.
AU - West, M. J.
AU - Wing, L. M.H.
AU - Bune, A. J.C.
AU - Graham, J. R.
PY - 1984/1/1
Y1 - 1984/1/1
N2 - Four placebo controlled, randomised crossover studies were carried out to investigate the effects of non-steroidal antiinflammatory drugs and analgesics on blood pressure control in treated hypertensive patients. Twelve patients completed one study comparing indomethacin, 25 mg tds, with placebo in 2 six week phases; there were increases in mean blood pressure (p < 0.01) of 9 mm Hg (casual), 8 mm Hg (supine) and 10 mm Hg (standing) in the indomethacin phase accompanied by a 50% reduction in plasma renin activity (p < 0.05) and a 47% decrease in plasma aldosterone concentration (p < 0.05). Similar studies on aspirin-SR, 650 mg daily (19 patients), and paracetamol, 1 g 8th hourly (20 patients), revealed only small changes in blood pressure, with a 2 mm Hg increase in supine diastolic blood pressure during aspirin therapy and a 4 mm Hg increase in supine and standing systolic blood pressure during paracetamol therapy (p < 0.05 for both) Nineteen patients completed a study with 4 three week phases, taking placebo, naproxen 250 mg mane and 500 mg nocte, sulndac 200 mg bd, and aspiring-SR 1950 mg bd. All threee active agents depressed plasma renin activity and plasma aldosterone concentration. Neither sulindac nor aspiring cuased any significant increases in blood pressure, and naproxen had little effect, though it did cause a 4 mm Hg increase in standing systolic pressure (p < 0.05). We conclude that the effects of indomethacin on control of blood pressure in treated hypertensive patients are not exhibited to the same extent by o ther durgs investigated, and that they are not dependent on the concomitant decreases in plasma renin activity or plasma aldosterone concentration. The importance of inhibition of prostaglandin sysnthesis remains unclear
AB - Four placebo controlled, randomised crossover studies were carried out to investigate the effects of non-steroidal antiinflammatory drugs and analgesics on blood pressure control in treated hypertensive patients. Twelve patients completed one study comparing indomethacin, 25 mg tds, with placebo in 2 six week phases; there were increases in mean blood pressure (p < 0.01) of 9 mm Hg (casual), 8 mm Hg (supine) and 10 mm Hg (standing) in the indomethacin phase accompanied by a 50% reduction in plasma renin activity (p < 0.05) and a 47% decrease in plasma aldosterone concentration (p < 0.05). Similar studies on aspirin-SR, 650 mg daily (19 patients), and paracetamol, 1 g 8th hourly (20 patients), revealed only small changes in blood pressure, with a 2 mm Hg increase in supine diastolic blood pressure during aspirin therapy and a 4 mm Hg increase in supine and standing systolic blood pressure during paracetamol therapy (p < 0.05 for both) Nineteen patients completed a study with 4 three week phases, taking placebo, naproxen 250 mg mane and 500 mg nocte, sulndac 200 mg bd, and aspiring-SR 1950 mg bd. All threee active agents depressed plasma renin activity and plasma aldosterone concentration. Neither sulindac nor aspiring cuased any significant increases in blood pressure, and naproxen had little effect, though it did cause a 4 mm Hg increase in standing systolic pressure (p < 0.05). We conclude that the effects of indomethacin on control of blood pressure in treated hypertensive patients are not exhibited to the same extent by o ther durgs investigated, and that they are not dependent on the concomitant decreases in plasma renin activity or plasma aldosterone concentration. The importance of inhibition of prostaglandin sysnthesis remains unclear
KW - Aspirin
KW - Indomethacin
KW - Naproxen
KW - Paracetamol
KW - Sulindac
KW - Syntase
UR - http://www.scopus.com/inward/record.url?scp=0021241671&partnerID=8YFLogxK
U2 - 10.3109/10641968409039582
DO - 10.3109/10641968409039582
M3 - Article
C2 - 6378437
AN - SCOPUS:0021241671
SN - 1064-1963
VL - 6
SP - 1077
EP - 1093
JO - Clinical and Experimental Hypertension
JF - Clinical and Experimental Hypertension
IS - 6
ER -